Essential Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Essential Partners’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.32K	Hold	90	–	–	﹤0.01%	1872
2026 Q2	$1.82K	Sell	90 -31	-26%	-$625	﹤0.01%	2010
2026 Q1	$2.37K	Sell	121 -79	-40%	-$1.93K	﹤0.01%	1936
2025 Q4	$5.36K	Sell	200 -50	-20%	-$1.29K	﹤0.01%	1399
2025 Q3	$6.66K	Buy	250 +94	+60%	+$2.43K	﹤0.01%	1311
2025 Q2	$3.58K	Buy	+156	New	+$3.87K	﹤0.01%	1146

Other funds holding AMPH

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Essential Partners's AMPH Position: Q3 2026 in Review

Essential Partners held its Amphastar Pharmaceuticals (AMPH) position steady in Q3 2026 at 90 shares worth $2.32K. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

Essential Partners first reported a position in AMPH in Q2 2025 and has held it in 6 quarters since. The position peaked at $6.66K in Q3 2025. 14 funds tracked by Wall St. Rank hold AMPH as of Q3 2026.

Essential Partners held 90 shares of Amphastar Pharmaceuticals worth $2.32K as of Q3 2026.
Essential Partners left its Amphastar Pharmaceuticals share count unchanged in Q3 2026.
Amphastar Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1872 holding.
Essential Partners first reported a position in Amphastar Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Amphastar Pharmaceuticals position peaked at $6.66K in Q3 2025.
14 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.